Pharmion has a treatment for small cell lung cancer that is about to enter a late-stage clinical trial.
Wyeth's Torisel didn't help small-cell lung cancer patients in a 2007 trial.
Patients with a particular type of lung cancer, called squamous cell carcinoma, were excluded from the trial because a previous study had found that they were more likely than other patients to experience bleeding of the lungs with Avastin therapy.
Bayer and biotech Onyx Pharmaceuticals announced a devastatingly disappointing result for their cancer pill Nexavar: They stopped a study of the drug in non-small cell lung cancer early because there was no chance it would reach its main goal of proving Nexavar extends patients' lives in that disease.
He explained that she had a non-small cell lung cancer that had started in her left lung.
The drug did seem to help non-small-cell lung cancer patients live slightly longer compared with a control group.
Among the bargain stocks, Berry says, is Cell Genesys (nasdaq: CEGE - news - people ), which has a number of products in late stage-three trials, including a vaccine for non-small cell lung cancer.
Additional studies will evaluate the effectiveness of the pill in glioblastoma, a lethal brain tumor, small-cell lung cancer and prostate cancer.
Tarceva has already produced promising results in a trial on patients with non-small cell lung cancer who had already been heavily treated with chemotherapy.
Do Bayer and Onyx have the option of modifying these studies so that they might, given this new information, stand a better chance of proving a benefit for Nexavar in non-small cell lung cancer?
It wasn't until Tarceva extended the lives of patients with non-small cell lung cancer that it became clear that OSI and Genentech actually did have a potential blockbuster on their hands.
The world's first patient trial is using a drug combination of Thalidomide and chemotherapy to treat small cell lung cancer, the most deadly form of lung cancer.
In a study conducted with many patients in Japan, 28% of non-small cell lung cancer patients saw their tumors shrink with Iressa, compared with 10% of Caucasians.
应用推荐